The Readout Loud

350 Folgen

1. 346: Zealand's obesity strategy and Immunovant's curious development plan

   Vom: 20.3.2025
2. 345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

   Vom: 13.3.2025
3. 344: Trump's FDA commissioner nominee takes the hot seat

   Vom: 6.3.2025
4. 343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

   Vom: 27.2.2025
5. 342: FDA cuts, zombie biotechs, and too much weight loss?

   Vom: 20.2.2025
6. 341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

   Vom: 13.2.2025
7. 340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

   Vom: 6.2.2025
8. 339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

   Vom: 30.1.2025
9. 338: Chinese biotechs, a WHO departure, and post-JPM thoughts

   Vom: 23.1.2025
10. 337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

    Vom: 15.1.2025
11. 336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

    Vom: 9.1.2025
12. 335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

    Vom: 19.12.2024
13. 334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

    Vom: 12.12.2024
14. 333: An H5N1 bird flu update and talent scarcity in the radiopharma field

    Vom: 5.12.2024
15. 332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

    Vom: 21.11.2024
16. 331: AbbVie’s stumble, Amgen’s tumble and more election fallout

    Vom: 14.11.2024
17. 330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

    Vom: 7.11.2024
18. 329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

    Vom: 31.10.2024
19. 328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

    Vom: 24.10.2024
20. 327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

    Vom: 17.10.2024